Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy

• Published in: HIV clinical trials Vol. 9; no. 6; p. 399
• Main Authors: Yang, Yong, Yap, Marline, Oo Tha, Naing, Paton, Nicholas I
• Format: Journal Article
• Language: English
• Published: England 01.11.2008
• Subjects: Absorptiometry, Photon; Adipose Tissue - pathology; Adult; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Body Composition - drug effects; Drug Therapy, Combination; Face; Female; HIV Infections - drug therapy; HIV Infections - virology; HIV-Associated Lipodystrophy Syndrome - chemically induced; HIV-Associated Lipodystrophy Syndrome - diagnosis; HIV-Associated Lipodystrophy Syndrome - pathology; Humans; Lasers; Male; Reverse Transcriptase Inhibitors - adverse effects; Reverse Transcriptase Inhibitors - therapeutic use; Stavudine - adverse effects; Stavudine - therapeutic use; Young Adult
• ISSN: 1528-4336
• DOI: 10.1310/hct0906-399

An objective method is needed for assessing facial fat changes in HIV-infected patients. To measure facial fat changes using three-dimensional laser scans (LS) and examine the relationship with clinically assessed lipoatrophy changes and dual-energy X-ray absorptiometry (DEXA) measured body composition changes in a cohort of patients taking combination antiretroviral therapy (ART). Consecutive patients taking ART for at least 12 months were recruited from an outpatient clinic. Clinical lipoatrophy assessment, LS of the face, and whole-body DEXA were performed at baseline and repeated after 12 months. Cheek surface volume (CSV) change and cheek surface point displacement (CPD) change were calculated from the LS using a standardized technique. Baseline and follow-up assessments were obtained in 146 patients. In the 102 patients with stable clinical lipoatrophy grade during follow-up, there was no CSV change (0.0 +/- 1.7 mL). In the 27 patients with clinical lipoatrophy progression, CSV decreased by 1.3 +/- 1.8 mL (p < .001 vs. stable patients); in the 17 patients with clinical facial lipoatrophy recovery, CSV increased by 1.0 +/- 1.7 mL (p = .092 vs. stable patients). CSV change was significantly related to limb fat change in the overall cohort (r = 0.32, p < .001). Multivariate regression analysis showed that stavudine use was a significant independent predictor of CSV (beta = -0.20, p = .038). Similar results were seen with calculation of CPD change. LS can detect facial lipoatrophy changes in a cohort of patients over time and can clearly detect the effects of individual drugs. This may be an objective and reliable method to assess facial fat change in future clinical trials.